Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
In the ADlong Phase 3b study, nearly all EBGLYSS-treated patients achieved meaningful skin improvement ( EASI -75) for up to four years 75% of patients achieved a high bar of near-complete skin clearance ( EASI -90) and 78% experienced significant itch relief (Pruritus NRS ≤ 4), one of the most
